C3 and COVID-19: Furthermore, interventions directed at suppressing a dysregulated complement cascade, including the administration of eculizumab (anti-C5 monoclonal antibody) (32), BDB-0001 (anti-C5a monoclonal antibody) (5), and AMY-101 (a compstatin-based C3 inhibitor) (33), have shown promising potential at attenuating the complement-mediated hyper-inflammatory response and severe outcomes in COVID-19 patients in several small case series, and should be investigated in the context of reducing TMA-mediated sequalae in the kidneys.